TNF and sarcopenia: This study demonstrates that coordinated targeting of TNF‐α–mediated inflammation with adalimumab and calcium channel dysfunction with GV‐58 is essential for restoring both muscle architecture and contractile function in poststroke sarcopenia, underscoring the therapeutic potential of dual‐modality intervention.